
Pfizer (PFE) Stock Forecast & Price Target
Pfizer (PFE) Analyst Ratings
Bulls say
Pfizer's stock outlook remains positive due to its robust annual sales of approximately $60 billion, primarily driven by its successful prescription drugs and vaccines. The company's strong portfolio, including top-selling products like Prevnar 13, Ibrance, and Eliquis, has been complemented by significant contributions from international markets, which account for 40% of total sales, particularly from emerging economies. Additionally, initiatives such as the Low-Income Subsidy eligibility expansion could enhance patient access and stabilize prescription volumes, further solidifying Pfizer's financial position.
Bears say
Pfizer is facing a negative outlook due to anticipated higher gross-to-net adjustments on its premium medicines, particularly Vyndaqel and Ibrance, which will impact revenue recognition in the early part of the year. The company also struggles with the market's potential underestimation of these adjustments, leading to uncertainty in financial projections. Additionally, the heavy reliance on prescription drugs and vaccines for revenue might exacerbate vulnerabilities in a competitive and evolving pharmaceutical landscape.
This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.
Pfizer (PFE) Analyst Forecast & Price Prediction
Start investing in Pfizer (PFE)
Order type
Buy in
Order amount
Est. shares
0 shares